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The Western Australia screening study was the last of the major trials of abdominal aortic aneurysm (AAA) screening to report late outcomes. 1 The accompanying systematic review published earlier 2 includes all available data from the existing randomized trials. It is doubtful that there will be more, and I agree with Frank Lederle 3 that this is the final say on the evidence base for population screening of AAA. So what does this study add, which was not known before? What can be concluded about AAA screening and whether it makes sense to roll it out internationally?
The Western Australia study is perhaps disappointing. It does not seem to confirm the positive late results of the other trials, such as the Multicentre Aneurysm Screening Study, which showed a 40% reduction in AAA-related mortality at final follow-up at 13 years. 4 It is suspected that the Australian population has a higher baseline level of previous abdominal investigation and thus a lower rate of previously undetected AAA. It is drummed into rural Australians that they are responsible for their health, so many may have had previous investigations where their AAA will have been diagnosed already. This seems different from the UK and Swedish populations, 5, 6 where the background level of investigation appears lower and the rate of undetected disease higher. Screening programs have more to offer populations such as these.
It seems likely based on the Western Australia study that population screening for AAA will not be recommended in that country, perhaps the correct decision for that environment. And yet the updated meta-analysis of all trials still finds that screening reduces AAA-related death in those invited, and an even stronger reduction in those who actually attend. Interestingly, unlike many other population programs, the updated meta-analysis of AAA screening also shows a borderline reduction in all-cause mortality for men in this age group.
Takagi and colleagues 2 also point out that men who are invited but do not attend have a higher subsequent AAArelated and all-cause mortality rate. This a reminder of the importance of ensuring that men understand the potential advantages of attending screening by good communication and increasing awareness. It would be unfortunate if it becomes another example of how health services fail small groups that are either disadvantaged or do not take their own health seriously.
Population screening for AAA in men is an evidence-based procedure. But the benefits will vary by country. In the United Kingdom where the prevalence of AAA is falling, commensurate with reduction in smoking habits, aneurysm screening remains cost-effective down to a prevalence of 0.35% (current prevalence in 65-year-old men in England: 1.1%).
7, 8 Elsewhere the benefits of AAA screening will depend on the prevalence of smoking and the general health of the population. Whereas AAA screening may not be justified in Australia, there are many parts of Europe in particular where high smoking rates suggest screening may well be effective.
Commencing population screening remains challenging. The costs of AAA screening are not insubstantial and include the screening test, surveillance for men with small and medium AAA, and the expense of elective repairs of AAA detected as a consequence of screening. However, treatment for patients with ruptured AAA is also costly and damaging to individuals and their families. Defining the optimal schedules for AAA surveillance has the potential to reduce some of the costs; ultrasound scan intervals may be reduced, without affecting efficiency.
Alternatively, there may be other ways to reduce costs. A number of countries are exploring the potential for a targeted approach, inviting selected high-risk groups of men and even high-risk groups of women, for whom hitherto AAA screening has not been cost-effective. 9 Smoking is the strongest risk factor for AAA, although having a first-degree relative with an AAA also increases the risk. Using electronic data to profile high-risk groups, with selective invitation for screening through family doctors, may be a way to introduce AAA screening in areas of low prevalence and in groups that previously have not been felt cost-effective, such as women. 10 Established AAA population screening programs for men in the United Kingdom and Sweden are productive and costeffective, despite the falling prevalence of all smokingrelated vascular diseases in these countries. There are many other parts of Europe where smoking rates remain high that could benefit from the introduction of AAA screening. The value of high-quality data, such as this month's updated meta-analysis, is that it provides the information required to enable these important strategic decisions to be made.
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